SIOX News and Press, Sio Gene Therapies Inc. From 02/04/21

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that it has received...

- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study throughout 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE ...

Citi analyst Neena Bitritto upgraded Passage Bio (PBIO) to a buy rating from neutral, noting a recent pressure on shares despite a range of potential clinical updates from the company in the next 12 months.The price target of $28 per share, reflects a ~33.8% upside to the close following a ~5...

This article reviews the Value & Momentum Breakouts 2020 trading year and addresses new strategies, models, and enhancements for 2021. 10 different model portfolios beat the S&P 500 in 2020 and six of these methods have beaten the S&P 500 consistently the past several year...

Sio Gene Therapies (SIOX) has agreed to sell its stake in Arvelle Therapeutics to Angelini Pharma, as part of that company’s cash acquisition of 100% of the stock of Arvelle Therapeutics for up to $960M.The transaction is expected to close in Q1 2021. Sio expects to receive an upfront ...

Company to receive up to $20 million in upfront and milestone payments from non-dilutive transaction Transaction extends cash runway into 2022 NEW YORK, N.Y. and RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a cli...

Final 2020 year-end report card for the MDA Breakout stocks now beating the S&P 500 for the fourth year in a row with +73.4% returns through 52 weeks. 2020 data shows that following the Momentum Gauges to avoid 20 weeks of negative signals delivered +94.7% returns in the remaining...

Palm Beach, FL – December 17, 2020 – Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial...

Gainers: Aethlon Medical (AEMD) +47%. Aclaris Therapeutics (ACRS) +32%. Tilray (TLRY) +23%. MiMedx Group (MDXG) +23%. Sio Gene Therapies (SIOX) +21%.Losers: Concord Medical Services Holdings (CCM) -43%. BioLineRx (BLRX) -30%. vTv Therapeutics (VTVT) -22%. Sensus Healthcare (SRTS) -1...

What Are The Best Penny Stocks To Buy Under $4.50? In 2020, there have been several factors helping investors find penny stocks to buy . Of course, there is never a guarantee in the stock market, and investing is an individual task. But, this year, several industries and sectors hav...